The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...

The healthcare pioneer shares insights on transformative diagnostics where precision medicine meets women’s health innovation ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amazon and Google parent Alphabet are set to report earnings, along with other tech companies including AI darling Palantir, and chipmaker Advanced Micro Devices. Pharmaceutical firms Novo Nordisk, ...

We recently published a list of Top 10 Best Dividend Stocks on Robinhood. In this article, we are going to take a look at where Merck & Co., Inc.

The most recent trading session ended with Merck (MRK) standing at $98.82, reflecting a -0.13% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 0 ...

Kennedy’s commitment to walk away from the potential windfall is a major reversal for the nominee, who in his ethics plan ...

Robert F. Kennedy Jr., Trump's pick to head the Department of Health and Human Services, faces scrutiny for fees he may earn from lawsuits against Merck.

With a volume of 4,802,873, the price of MRK is down -0.11% at $98.84. RSI indicators hint that the underlying stock is currently neutral between overbought and oversold. Next earnings are expected to ...

Robert F. Kennedy Jr. also disclosed that he had reached at least one settlement agreement with a company or individual that ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...